Drug Trial Radar · NCT07318870
Efficacy of Probenecid on Cluster Seizures During Anti Seizure Medication Withdrawal in Presurgical Focal Epilepsy Video-EEG Monitoring
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Aug 24, 2026
Primary completion
Sep 2029
Study completion Sep 2029
Sponsor
- Lead sponsor
- Fondation Ophtalmologique Adolphe de RothschildResearch network
- Sponsor type
- Research network
- First posted
- Jan 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ProbCluster trial aims at making the proof of concept of antiseizure efficacy of the old antigout PBN in SC, in which Panx1 involvement is relevant on SC pathophysiology and in which efficient therapies are still lacking. The trial will be performed on patients with focal epilepsy in presurgical evaluation undergoing video-EEG monitoring, a setting characterized by a high risk of SC and an efficient video-EEG monitoring of seizures, reducing the risk of erroneous report based on patient home assessment. PBN is a good candidate for a repurposing in epilepsy, due to its brain penetration allowing Panx1 in situ blockade and of its good security profile. The repurposing process allows a faster, safer and cheaper development.
Conditions
- Focal Epilepsy
Interventions
ProbenecidDrug
Oral administration of PBN at a dose of 3g in adults or children weighting \> 50 kg; at a dose of 2g in children weighting 35 to 50 kg; and at a dose of 1g in children weighting 20 to 34 kg.
PlaceboOther
Placebo administration in a scheme similar to experimental treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cessation of seizure recurrence in patients experiencing a cluster seizureTime frame: Time period from Day 0 to maximum Day 21
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Hôpital Fondation A de Rothschild
Paris, France · Recruiting
Hôpital Fondation A de Rothschild
Paris, France · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.